BEAT-DKD

Biomarker enterprise to attack DKD

FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 5
Grant agreement number
115974

Contributions
IMI Funding
15 085 937
EFPIA in kind
13 226 100
Other
797 001
Total Cost29 109 038

Summary

Diabetic kidney disease (DKD) is a common complication of diabetes, and DKD is now the most common form of chronic kidney disease. There is no effective way to prevent or treat DKD, leaving many patients in extremely poor health and facing high mortality rates. The BEAt-DKD project aims to deliver tools and knowledge that will facilitate the development of new, personalised treatments for DKD. Among other things, the project will identify and validate biological markers (biomarkers) to help researchers track whether a patient’s condition has worsened, and whether a treatment is working for them. They will also work to identify different sub-groups of patients that could respond differently to certain treatments. The results will therefore pave the way for the development of effective personalised treatments for DKD.

Participants Show participants on map

EFPIA companies
  • AbbVie Inc., North Chicago, Illinois, United States
  • Astellas Pharma Europe BV, Leiden, Netherlands
  • Bayer AG, Berlin, Germany
  • Eli Lilly and Company Ltd, Basingstoke, United Kingdom
  • Novo Nordisk A/S, Bagsvaerd, Denmark
  • Sanofi-Aventis Deutschland GMBH, Frankfurt / Main, Germany
Universities, research organisations, public bodies, non-profit groups
  • Academisch Ziekenhuis Groningen, Groningen, Netherlands
  • Chu Hopitaux De Bordeaux, Talence, France
  • Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy
  • Itä-Suomen yliopisto, Kuopio, Finland
  • Klinikum der Universitaet Regensburg, Regensburg, Germany
  • Lunds Universitet, Lund, Sweden
  • Medizinische Universitaet Wien, Vienna, Austria
  • Medizinische Universität Innsbruck, Innsbruck, Austria
  • SIB Institut Suisse De Bioinformatique, CH-660-0733998-3, Genève, Switzerland
  • The University of Exeter, Exeter, United Kingdom
  • Universitaetsklinikum Freiburg, Freiburg, Germany
  • University of Bristol, Bristol, United Kingdom
  • University of Dundee, Dundee, United Kingdom
  • University of Helsinki, University of Helsinki, Helsinki, Finland
  • University of Hull, Hull, United Kingdom
  • University of Leeds, Leeds, United Kingdom
  • University of Oxford, Oxford, United Kingdom
  • University of Turku, Turku, Finland
  • Università degli Studi di Bari Aldo Moro, Bari, Italy
  • Universitätsklinikum Erlangen, Erlangen, Germany
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Lipotype GmbH, Dresden, Germany
Associated partners
  • Jdrf International, New York, United States
Third parties
  • Apuliabiotech, Bari, Italy
  • Semmelweis University, Budapest, Hungary
  • Slaski Uniwersytet Medyczny w Katowicach, Katowice, Poland
  • University of Glasgow, Glasgow, United Kingdom
  • Varsinais-Suomen sairaanhoitopiirin kuntayhtymä (Turku University Hospital), Turku, Finland
Non EFPIA companies
  • University Of Michigan The Regents Of The University Of Michigan, Ann Arbor, United States

CONTACT

Project coordinator
Maria Gomez
Lunds universitet
+46 40 391058
maria.gomez[at]med.lu.se